Medicare coverage for Incruse Ellipta (umeclidinium) depends on whether the medication is available in a preferred generic or brand-name formulation and your specific Medicare plan [1].
What is Incruse Ellipta used for?
Incruse Ellipta is a once-daily bronchodilator medication prescribed for the long-term treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including emphysema and chronic bronchitis [1]. It is not used for immediate relief of COPD symptoms [1].
How does Medicare typically cover COPD medications?
Medicare Part D, the prescription drug benefit, covers a wide range of medications used to manage COPD. Coverage for specific inhalers like Incruse Ellipta is determined by the drug formulary of your Medicare Part D plan. Drug formularies are lists of prescription drugs covered by a plan, often organized into tiers that affect out-of-pocket costs [2].
Will my Medicare plan cover Incruse Ellipta?
To determine if your specific Medicare plan covers Incruse Ellipta, you should check your plan's formulary or contact your plan provider directly. If Incruse Ellipta is not on your plan's formulary, or if it is on a higher cost tier, you may have higher out-of-pocket expenses [2]. Some plans may require prior authorization or step therapy, meaning you might need to try a less expensive medication first [3].
Are there less expensive alternatives to Incruse Ellipta?
Other bronchodilator inhalers for COPD are available, and some may be covered by Medicare at a lower cost depending on your plan's formulary. These could include other long-acting muscarinic antagonists (LAMAs) or medications from different drug classes like long-acting beta-agonists (LABAs) or combination inhalers [1, 2].
When does patent exclusivity for Incruse Ellipta expire?
DrugPatentWatch.com tracks patent information for medications. The patent exclusivity for Incruse Ellipta will expire based on the patent filings and any extensions or challenges [4]. This information can be found on specialized drug patent databases [4].
Sources:
1. Incruse Ellipta. GSK.
2. Medicare.gov. Prescription Drug Coverage.
3. Medicare.gov. Prior Authorization.
4. DrugPatentWatch.com.